Editas Medicine (EDIT): Quarterly Revenue Growth

Official company branding of Editas (EDIT)

Cash flow gap risks and fierce market competition are forcing Editas Medicine, Inc. (EDIT) to pivot its strategy toward licensing. Nevertheless, the brand maintains its authority due to the precision of its CRISPR platform. Quarterly revenue changes on GURU.Markets reflect its status as a scientific pioneer in genetic treatment, where 37.50 is recorded as the baseline value for the current dynamics of the business's commercial expansion.

EDIT (Editas) Quarterly Sales Growth Rate history from 07/04/2022 to 11/21/2026

Analytical breakdowns and data insights for company Editas (EDIT)

- stock price and consensus target price:
General company analysis:editasmedicine.com (EDIT)
Manufactured products of Editas Medicine Inc

Editas Medicine, Inc. (EDIT) focuses on the commercialization of intellectual property rights and the development of gene-editing technologies. This metric measures the percentage deviation of current quarter revenue compared to the same period last year, revealing the business's scaling pace. The current value of 37.50 allows investors to assess the effectiveness of management's updated strategy amid market volatility. GURU.Markets analysts recommend tracking changes in quarterly sales volume to verify the issuer's fundamental stability.

Competitors of Editas Medicine, Inc.

TEM - Revenue Growth QoQ|Quarterly Sales Growth Rate qiagen.com QGEN|IONS: Quarterly Revenue Growth|Repligen Corp - Quarterly Revenue Increase|RNA (Avidity Corp) - Quarterly Revenue Growth|CRISPR Therapeutics Corp - Revenue Dynamics QoQ|Revenue Growth QoQ genedx.com (WGS)|Quarterly Revenue Growth ultragenyx.com (RARE)|Quarterly Revenue Growth BEAM (Beam Therapeutics Inc)|Sarepta Therapeutics Inc (SRPT) - Quarterly Revenue Growth Rate|twistbioscience.com - Quarterly Revenue Growth|10x Genomics, Inc. - Sales Change QoQ|NTLA (Intellia Corp) - Quarterly Sales Growth|Quarterly Sales Growth stoketherapeutics.com|Quarterly Sales Growth BLFS|Quarterly Sales Growth Wave Life Sciences Corp (WVE)|Quarterly Revenue Growth MAZE|Quarterly Sales Growth Rate Sionna Therapeutics Inc|Revenue Growth QoQ Prime Medicine Corp PRME|tayshagtx.com (TSHA) - Quarterly Revenue Growth Rate|QURE - Revenue Growth QoQ|MeiraGTx Holdings (MGTX) - Quarterly Sales Growth|Regenxbio (RGNX) - Revenue Growth QoQ|SLDB - Quarterly Sales Growth Rate|OCGN (Ocugen Inc) - Quarterly Revenue Growth|Revenue Growth QoQ PACB|Revenue Growth QoQ Benitec (BNTC)|Design Therapeutics Inc - Sales Growth QoQ|Revenue Growth QoQ Rocket Pharma RCKT|Quarterly Revenue Growth 4DMT FDMT|LXEO - Revenue Growth QoQ|Quarterly Revenue Growth Rate Korro Bio Inc.|SLN: Quarterly Revenue Growth|ProQR - Quarterly Revenue Increase|CDXS (Codexis) - Quarterly Revenue Growth|Sangamo (SGMO) - Quarterly Sales Growth Rate|Quarterly Revenue Growth NAUT|Quarterly Sales Growth Metagenomi, Inc. MGX|Revenue Growth QoQ Precision BioSciences DTIL|Quarterly Revenue Increase GBIO|BOLD - Revenue Growth QoQ|Quarterly Sales Growth Rate Exicure Inc. XCUR|Imunon, Inc. (IMNN) - Revenue Growth QoQ|RXi Pharmaceuticals - Quarterly Revenue Increase|MBIO (Mustang Bio) - Quarterly Revenue Growth|Sales Growth QoQ RNAZ (transcodetherapeutics.com)|Revenue Growth QoQ Bionano (BNGO)|Applied DNA Sciences - Sales Growth QoQ|Quarterly Revenue Growth BLUE (bluebirdbio.com)|ImmunoPrecise Antibodies (IPA) - Quarterly Revenue Growth Rate|omegatherapeutics.com - Quarterly Revenue Growth|Revenue Change vs Previous Quarter Singular Genomics Systems Inc (OMIC)|RGLS: Quarterly Revenue Growth|Syros Pharmaceuticals, Inc (SYRS) - Quarterly Revenue Growth|TBIO (telesisbio.com) - Quarterly Revenue Growth|TCON: Quarterly Revenue Increase|Revenue Growth QoQ Unity Biotechnology, Inc (UBX)